In just concluded Meeting of Board of Directors, the Board approved and considered the following items: 1. Audited Standalone & Consolidated Financial Results for the Quarter and Year ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Gennex Laboratories reported FY2026 consolidated revenue of Rs 18,098.67 Lakhs, up 22.4% from Rs 14,833.31 Lakhs in FY2025. Net profit grew 15.7% to Rs 2,097.88 Lakhs from Rs 1,812.49 Lakhs. However, auditors issued Qualified Opinions on both standalone and consolidated results due to unconfirmed balances of current assets, liabilities, receivables and payables with unascertained impact. The company is yet to install transaction traceability software. More concerning is negative operating cash flow of Rs 6,365.39 Lakhs (consolidated) and Rs 4,018.28 Lakhs (standalone), driven by a sharp rise in trade receivables (up 208% to Rs 4,355.65 Lakhs) and inventories (up 50% to Rs 5,388.75 Lakhs). Borrowings nearly tripled to Rs 3,595.37 Lakhs.
The qualified audit opinion and negative operating cash flow are significant red flags for investors. While revenue growth exceeds 20%, the inability to confirm major balance sheet items and heavy reliance on borrowings raise concerns about financial transparency and liquidity. The stock may face selling pressure.